Dr. Richard Steven Bercik, MD

Dr. Bercik practices at Yale Medicine in New Haven, Connecticut.

Dr. Bercik's NPI, 1942298013, was assigned on October 12, 2005. Dr. Bercik graduated from Rutgers New Jersey Medical School in 1983. Dr. Bercik holds Connecticut license 040946.

Dr. Bercik's primary practice is Yale Medicine, at 50 Division St, New Haven, CT 06511 in South Central Ct County. The practice phone is (203) 785-2140.

Dr. Bercik's primary practice is Yale Medicine in New Haven, Connecticut. Dr. Bercik is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Bercik to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bercik practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecology is Dr. Bercik's primary specialty in the NPI Registry, under taxonomy code 207VG0400X. Dr. Bercik is board certified in female pelvic medicine and reconstructive surgery by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Bercik's licenses on file in 5 states: Connecticut, Florida, California, New Jersey and New York.

Dmand AI lists bladder disease, hysterectomy, menopause, pelvic prolapse, UTI, vaginal prolapse repair and vaginal repair among the conditions Dr. Bercik treats.

CMS data shows 255 Medicare services from Dr. Bercik across 7 procedure codes in 2024, for 130 Medicare patients. Medicare paid $22,581 for them.

CMS counts 130 Medicare patients who saw Dr. Bercik in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.07, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bercik's median patient age at 71, with 98% women.

In 2024, Dr. Bercik wrote 367 Medicare Part D claims for 120 patients. 83% of them were for generic drugs. CMS names the drug for 286 of them, across 7 drugs with 11 or more claims each, at $43,937 in total drug cost. In 2023, CMS named 288 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Bercik for performance year 2024, reported as part of a group. Dr. Bercik accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bercik as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Bercik, published from 2009 to 2024. 2011 was the busiest year, with 2. The most frequent topics are Homeodomain Proteins, Ligaments and NIH 3T3 Cells. Dr. Bercik's most frequent co-authors are Hugh S. Taylor, MD, Vaagn Andikyan, MD and Leslie Minor Rickey, MD.

Dmand AI links Dr. Bercik to 2 clinical trials, 2 of them phase 4 studies. Conditions studied include Pelvic Organ Prolapse and Prolapse. ASTORA Women's Health sponsors the most, 2.

CMS Open Payments shows 6 general payments to Dr. Bercik from 5 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 75% of the total. Covidien LP paid the most, $1,197. It also lists 72 research payments totaling $209,293 from 2016 to 2021.

Dmand AI lists 8 awards for Dr. Bercik, most recently Best Surgical Educator in 2014.

Dr. Bercik graduated from Rutgers New Jersey Medical School in 1983. Dr. Bercik is a member of American College of Obstetricians and Gynecologists.

Dr. Bercik is in network with 16 carriers, including Aetna, United Healthcare and Cigna. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.